Updated safety analysis

 

Ongoing safety evaluations from ocrelizumab clinical trials and associated open-label extension periods, as well as selected post-marketing safety data.

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Hauser SL, Kappos L, Montalban X, et al. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, Sweden; 11-13 September 2019.
Download PDF (1283kb)
Cases Reported as Progressive Multifocal Leukoencephalopathy in Ocrelizumab-Treated Patients With Multiple Sclerosis
Clifford DB, Gass A, Richert N, et al. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, Sweded; 11-13 September 2019.
Download PDF (1099kb)

Prescribing information

Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.
Updated safety analysis